A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma

Patients with recurrent or metastatic cervical cancer have limited therapeutic options. Here the authors report efficacy and safety of camrelizumab (anti-PD-1 antibody) in combination with famitinib (anti-angiogenic agent) in pre-treated recurrent or metastatic squamous cervical cancer.

Bibliographic Details
Main Authors:	Lingfang Xia, Qi Zhou, Yunong Gao, Wenjing Hu, Ge Lou, Hong Sun, Jianqing Zhu, Jin Shu, Xianfeng Zhou, Rong Sun, Xiaohua Wu
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-12-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-022-35133-4

Similar Items

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study
by: Quanren Wang, et al.
Published: (2022-05-01)

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 studyResearch in context
by: Xi Ding, et al.
Published: (2023-07-01)

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
by: Ying Liu, et al.
Published: (2024-02-01)

Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
by: Ming Gao, et al.
Published: (2025-01-01)

Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma
by: Shuwen Yang, et al.
Published: (2023-01-01)

Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma
by: Changlong Hou, et al.
Published: (2024-03-01)

Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer
by: Meng Yuan, et al.
Published: (2022-12-01)

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study
by: Yunyan Mo, et al.
Published: (2024-01-01)

A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma
by: Houyu Ju, et al.
Published: (2023-08-01)

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland
by: Xiaoting Liu, et al.
Published: (2024-07-01)

Anlotinib plus camrelizumab achieved long‐term survival in a patient with metastatic esophageal neuroendocrine carcinoma
by: Lingxiao Zhou, et al.
Published: (2023-09-01)

Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
by: Yinfang Gu, et al.
Published: (2025-02-01)

Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study
by: Rui-Qin Zhou, et al.
Published: (2023-05-01)

Sintilimab plus HPV vaccine for recurrent or metastatic cervical cancer
by: Xian Zhang, et al.
Published: (2024-11-01)

Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China
by: Rui Guo, et al.
Published: (2023-12-01)

Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
by: Zhou WJ, et al.
Published: (2024-12-01)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
by: Yusheng Guo, et al.
Published: (2022-03-01)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
by: Taihang Shao, et al.
Published: (2022-08-01)

Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma
by: Wen-Chen Tang, et al.
Published: (2023-07-01)

Prospective multicenter study of camrelizumab in real-world settings for asian patients with esophageal squamous cell carcinoma
by: Tingting Li, et al.
Published: (2024-11-01)

Efficacy and toxicity of anlotinib plus camrelizumab versus anlotinib plus S-1 as second-line therapy for advanced esophageal squamous cell carcinoma: A real-world retrospective study
by: Wei Zhang, et al.
Published: (2024-10-01)

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
by: Ming Zhang, et al.
Published: (2022-03-01)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
by: Jun Ni, et al.
Published: (2023-04-01)

Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
by: Fei Chen, et al.
Published: (2022-08-01)

Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors
by: Jie Shen, et al.
Published: (2023-03-01)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
by: Baihua Zhang, et al.
Published: (2023-02-01)

Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China
by: Hongbin Dai, et al.
Published: (2023-02-01)

The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study
by: Yin GQ, et al.
Published: (2022-06-01)

Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study
by: Xingxiang Pu, et al.
Published: (2023-04-01)

Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
by: Pingyu Chen, et al.
Published: (2024-05-01)

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
by: Qingyuan Zhang, et al.
Published: (2022-10-01)

Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study
by: Yu Lin, et al.
Published: (2024-11-01)

Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma
by: Li Chao, et al.
Published: (2024-03-01)

Correction: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Published: (2022-06-01)

Successful treatment of recurrent sarcomatous choledochal carcinoma with camrelizumab and apatinib
by: Shilei Li
Published: (2023-11-01)

Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma
by: Lin Li, et al.
Published: (2024-06-01)

Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study
by: Shujing Shen, et al.
Published: (2024-07-01)

Case Report: Camrelizumab plus gemcitabine followed by concurrent chemoradiation for HPV-positive and PD-L1-positive tonsillar squamous cell carcinoma
by: Xuesong Li, et al.
Published: (2025-03-01)

Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial
by: Jing Chen, et al.
Published: (2023-05-01)

A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
by: Xiaomi Li, et al.
Published: (2023-08-01)